Who are Ticagrelor loading dose's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Clopirin 2, Prasugrel based standard DAPT, clopidogrel bisulfate + aspirin, Aspirin and clopidogrel / Prasugrel, bivalirudin + clopidogrel + aspirin, Ticagrelor 60.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ticagrelor-loading-dose.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Ticagrelor loading dose — Competitive Intelligence Brief

Ticagrelor loading dose (Ticagrelor loading dose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: P2Y12 platelet receptor antagonist. Area: Cardiovascular.

marketed P2Y12 platelet receptor antagonist P2Y12 receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Ticagrelor loading dose (Ticagrelor loading dose) — Icahn School of Medicine at Mount Sinai. Ticagrelor is a P2Y12 platelet receptor antagonist that irreversibly blocks ADP-induced platelet aggregation to prevent thrombotic events.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Ticagrelor loading dose TARGET	Ticagrelor loading dose	Icahn School of Medicine at Mount Sinai	marketed	P2Y12 platelet receptor antagonist	P2Y12 receptor
Clopirin 2	Clopirin 2	Jeil Pharmaceutical Co., Ltd.	marketed	P2Y12 receptor antagonist / Antiplatelet agent	P2Y12 receptor
Prasugrel based standard DAPT	Prasugrel based standard DAPT	Research Maatschap Cardiologen Rotterdam Zuid	marketed	P2Y12 receptor antagonist (thienopyridine)	P2Y12 receptor
clopidogrel bisulfate + aspirin	clopidogrel bisulfate + aspirin	Seoul National University Hospital	marketed	Dual antiplatelet agent	P2Y12 receptor (clopidogrel); cyclooxygenase (aspirin)
Aspirin and clopidogrel / Prasugrel	Aspirin and clopidogrel / Prasugrel	Assistance Publique - Hôpitaux de Paris	marketed	Antiplatelet agent (dual therapy combination)	COX-1 (aspirin); P2Y12 receptor (clopidogrel/prasugrel)
bivalirudin + clopidogrel + aspirin	bivalirudin + clopidogrel + aspirin	Centre Hospitalier de PAU	marketed	Anticoagulant + antiplatelet combination	Thrombin (Factor IIa), P2Y12 receptor, cyclooxygenase
Ticagrelor 60	Ticagrelor 60	Sheffield Teaching Hospitals NHS Foundation Trust	marketed	P2Y12 receptor antagonist (antiplatelet agent)	P2Y12 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (P2Y12 platelet receptor antagonist class)

Icahn School of Medicine at Mount Sinai · 2 drugs in this class
Collegium Medicum w Bydgoszczy · 1 drug in this class
Massachusetts General Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ticagrelor loading dose — Competitive Intelligence Brief. https://druglandscape.com/ci/ticagrelor-loading-dose. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab